- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04386213
Trial for MicroPort's DCB
A Prospective, Multicenter, Randomized Trial in Evaluating the Safety and Efficacy of the Paclitaxel Drug-coated Coronary Artery Balloon Catheter in Patients With Coronary Artery In-stent Restenosis Compared to SeQuent® Please Paclitaxel Drug-coated Coronary Artery Balloon Catheter
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Ling Tao
- Phone Number: 13636498543
- Email: clfeng@microport.com
Study Contact Backup
- Name: Ling Tao
- Phone Number: 029-84775507
- Email: webmaster@fmmu.edu.cn
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- General Inclusion Criteria:
1.18-75 years of age, males or non-pregnant females; 2.With silent ischemia evidence, patients with stable or unstable angina, or in patients with old myocardial infarction; 3.Restenosis after the first stent implantation, and more than 90 days after the stent implantation; 4.Patients with indications for coronary artery bypass graft surgery; 5.To understand the purpose of testing, voluntary and informed consent, patients undergoing invasive imaging follow-up.
Angiographic Inclusion Criteria:
- One or two target lesions;
- Restenosis in the stent (including bare stent, permanent coating and biodegradable coating) : Mehran I, II and III stenosis;The diameter of the reference vessel ranges from 2.0mm to 4.0mm, and the length ≤40mm;
- The original stent diameter stenosis before surgery must be ≥70% or ≥50% with local ischemia;
- There should be no more than two lesions requiring interventional treatment, and the distance between the two lesions must be >10mm.
Exclusion Criteria:
General Exclusion Criteria:
- Within 1 week of any acute myocardial infarction or myocardial enzymes did not return to normal;
- Severe congestive heart failure (NYHA III and above) ,or left ventricular ejection fraction <30% (ultrasound or left ventricular angiography);
- The unstable arrhythmia, such as high risk ventricular extrasystole and ventricular tachycardia;
- Blood test prompted platelet counts of less than 100x10E9/L or greater than 700x10E9/L, white blood cells than 3x10E9/L; which was judged to be clinically significant by the researchers;
- Preoperative renal function serum creatinine >2.0mg/DL; receiving hemodialysis;
- Subjects with bleeding tendency, antiplatelet preparation and anticoagulant treatment contraindications, subjects unable to receive antithrombotic treatment, or subjects unable to tolerate DAPT treatment for three months;
- Previous history of peptic ulcer or gastrointestinal bleeding within 6 months;
- Patients with cerebral vascular accident or transient ischemic attack (TIA) within the previous 6 months, or with permanent neurological defects that may lead to non-compliance with the protocol;
- Allergic to aspirin, heparin, contrast agent, polylactic acid polymer and paclitaxel;
- The life expectancy of the subjects is less than 12 months;
- The researcher judged that the subjects had poor compliance and could not complete the study as required;Or for other reasons that the researchers consider inappropriate;
- Subjects who are participating in any other clinical trial, or who have participated in clinical trials of other drugs or medical devices before being enrolled and have not reached the main study endpoint;
- Pregnant or breast-feeding female subjects (women who may be pregnant must undergo a pregnancy test 7 days prior to baseline surgery).
Angiographic Exclusion Criteria:
- In-stent restenosis without successful predilatation;
- Stent restenosis of vein grafts;
- Bridge stent restenosis;
- All three vessels were diseased and needed revascularization;
- Vessel diameter of branch opening in bifurcation lesions ≥2.5mm;
- Complete occlusion of blood flow at TIMI level 0 (Mehran type IV stenosis);
- The lesion was located in the left trunk and within 2mm from the opening.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Paclitaxel Drug-coated Balloon
|
treat the petients with coronary artery in-stent restenosis
|
Active Comparator: SeQuent® Please Paclitaxel Drug-coated Balloon
|
treat the petients with coronary artery in-stent restenosis
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
In-segment Late Lumen Loss
Time Frame: 9 months after coronary angiography
|
In-segment Late Lumen Loss
|
9 months after coronary angiography
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Device success
Time Frame: during the procedure
|
defined as residual stenosis ≤30% and TIMI3 blood flow after drug-eluting balloon dilation.
|
during the procedure
|
Procedural success
Time Frame: Immediately after the index procedure
|
Defined as target lesions with residual stenosis ≤30% and TIMI3 blood flow after any interventional treatment, without thrombus or dissection need interention.
|
Immediately after the index procedure
|
Clinical success
Time Frame: At time of procedure up to 7 days in hospital
|
Defined as the absence of device-related composite endpoint events during hospitalization (up to 7 days after surgery) on the basis of procedural success.
|
At time of procedure up to 7 days in hospital
|
Device-oriented composite endpoints (Target Lesion Failure)
Time Frame: 1 month, 6 months, 9 months, 1 year and 2 years after index procedure
|
TLF is defined as the composited endpoints of cardiac death, target vessel myocardial infarction and ischemia-driven target lesion revascularization.
|
1 month, 6 months, 9 months, 1 year and 2 years after index procedure
|
Patient-oriented composite endpoint (PoCE)
Time Frame: 1 month, 6 months, 9 months, 1 year and 2 years after index procedure
|
Patient-oriented composite endpoint is defined as all cause death, all myocardial infarction, and any revascularization.
|
1 month, 6 months, 9 months, 1 year and 2 years after index procedure
|
Death (Cardiac, Non-cardiac)
Time Frame: 1 month, 6 months, 9 months, 1 year and 2 years after index procedure
|
Defined as death due to the following causes. Acute myocardial infarction; cardiac perforation/cardiac tamponade; arrhythmia or abnormal conduction; death due to surgical complications, including bleeding, vascular repair, transfusion response, or coronary artery bypass surgery; anything that does not rule out death from cardiac causes. Non-cardiac death: defined as death from causes other than the above cardiac causes. |
1 month, 6 months, 9 months, 1 year and 2 years after index procedure
|
The number and rate of Myocardial Infarction (MI)
Time Frame: 1 month, 6 months, 9 months, 1 year and 2 years after index procedure
|
Attributable to target vessel (TV-MI), Not attributable to target vessel (NTV-MI)
|
1 month, 6 months, 9 months, 1 year and 2 years after index procedure
|
The number and rate of Target Lesion Revascularization (TLR)
Time Frame: 1 month, 6 months, 9 months, 1 year and 2 years after index procedure
|
Ischemia-driven TLR (ID-TLR), Not ischemia-driven TLR (NID-TLR)
|
1 month, 6 months, 9 months, 1 year and 2 years after index procedure
|
The number and rate of Target Vessel Revascularization (TVR)
Time Frame: 1 month, 6 months, 9 months, 1 year and 2 years after index procedure
|
Ischemia-driven TVR (ID-TVR), Not ischemia-driven TVR (NID-TVR)
|
1 month, 6 months, 9 months, 1 year and 2 years after index procedure
|
The number and rate of Any Revascularization
Time Frame: 1 month, 6 months, 9 months, 1 year and 2 years after index procedure
|
Ischemia-driven , Not ischemia-driven
|
1 month, 6 months, 9 months, 1 year and 2 years after index procedure
|
The number and rate of Thrombosis (per ARC definition)
Time Frame: 1 month, 6 months, 9 months, 1 year and 2 years after index procedure
|
Timing (acute, sub-acute, late and very late) Evidence (Definite and Probable)
|
1 month, 6 months, 9 months, 1 year and 2 years after index procedure
|
In-segment angiography binary restenosis (ABR, %)
Time Frame: 9 months after index procedure
|
Defined as the proportion of subjects with restenosis occurring in the target lesion segment and the diameter stenosis ≥50%.Quantitative coronary angiography analysis (QCA) calculation (1- 9 months after the operation of the original stent restenosis in-segment residual minimum lumen diameter / reference vessel diameter) ×100%
|
9 months after index procedure
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- PROMISE-DCB
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery In-stent Restenosis
-
B. Braun Medical Inc.Infraredx; Bright Research PartnersWithdrawnCoronary Artery Restenosis | In-stent Restenosis | In-stent Coronary Artery Restenosis
-
Second Affiliated Hospital, School of Medicine,...West China Hospital; The Third Xiangya Hospital of Central South University; Shanghai... and other collaboratorsUnknownCoronary In-stent RestenosisChina
-
Spanish Society of CardiologyAbbott Medical Devices; Terumo Medical Corporation; Fundación de Investigación... and other collaboratorsUnknownCoronary In-stent RestenosisSpain
-
Rambam Health Care CampusCompletedIn-stent Coronary Artery RestenosisIsrael
-
Medstar Health Research InstituteWithdrawn
-
Medstar Health Research InstituteUnknownIn-stent Coronary Artery RestenosisUnited States
-
Biotronik AGCompletedIn-stent Coronary Artery RestenosisGermany
-
DK Medical Technology (Suzhou) Co., Ltd.Core Medical (Beijing) Co., Ltd.Active, not recruitingCoronary In-stent RestenosisChina
-
Ospedale Santa Maria GorettiWithdrawnIn-stent Coronary Artery RestenosisItaly
-
MINVASYSEuropean Cardiovascular Research CenterCompletedIn-stent Coronary Artery RestenosisFrance
Clinical Trials on coronary artery in-stent restenosis
-
Helse Stavanger HFCompletedRestenosis or Adverse Cardiovascular EventNorway
-
Haukeland University HospitalOslo University Hospital; Aarhus University Hospital Skejby; University Hospital... and other collaboratorsUnknownAcute ST Segment Elevation Myocardial InfarctionNorway, Denmark
-
Sohag UniversityRecruitingAngiotensin Converting Enzyme rs (1799752) Gene Polymorphism and Development of In-Stent Restenosis in Patients With Stable Coronary Artery DiseasesEgypt
-
Silesian Centre for Heart DiseasesUnknownCoronary Artery Disease | Restenoses, Coronary | In-stent Restenosis | Contact Allergy | Metal Allergy
-
Bursa Postgraduate HospitalCompleted
-
Micell TechnologiesYale Cardiovascular Research Group; North American Science Associates Inc.; Baim...Not yet recruiting
-
Abbott Medical DevicesCompletedMyocardial Ischemia | Coronary Artery Disease | Vascular Disease | Coronary Artery Stenosis | EverolimusNetherlands, Germany, Denmark
-
Micell TechnologiesCardialysis BV; ClinLogix. LLCUnknown
-
Fundación Pública Andaluza Progreso y SaludUnknownUnprotected Left Main Coronary Artery StenosisSpain
-
Ho Young HwangCompletedCoronary Artery Disease | Morphologic ChangeKorea, Republic of